Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06317220 · ClinicalTrials.gov registry record · Phase 2
Vedolizumab for the Treatment of Collagenous Gastritis
A Phase 2 study of Collagenous Gastritis, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT06317220 is a Phase 2 study of Collagenous Gastritis that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06317220, a Phase 2 study of Collagenous Gastritis, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about how vedolizumab may affect patients with collagenous gastritis (CG). The main questions it aims to answer are: * Whether vedolizumab can reduce CG symptoms * Whether vedolizumab is safe to take for patients with CG Participants in this study will: * Receive vedolizumab through an IV ("infusion") * Complete a survey at each infusion visit * Have blood collected at each infusion visit * Undergo an endoscopy with biopsy at 2 timepoints
Conditions Studied
Interventions
- BIOLOGICAL Vedolizumab
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06317220
The ClinicalTrials.gov registry entry for NCT06317220 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Collagenous Gastritis appearing as the primary indexed condition, and to 1 intervention - of which Vedolizumab is the first listed.
NCT06317220 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06317220 about?
NCT06317220 is a clinical study titled "Vedolizumab for the Treatment of Collagenous Gastritis". The goal of this clinical trial is to learn about how vedolizumab may affect patients with collagenous gastritis (CG). The main questions it aims to answer are: * Whether vedolizumab can reduce CG symptoms * Whether vedolizumab is safe to take for patients with CG Participants in this study will: ...
What is the current status of trial NCT06317220?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2024-12-03. Estimated completion is 2026-10.
What conditions does trial NCT06317220 study?
This clinical trial studies the following conditions: Collagenous Gastritis.
What interventions are being tested in trial NCT06317220?
The interventions under investigation include: Vedolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06317220?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06317220 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.